
Catamaran Bio
Catamaran Bio is a biotechnology company that researches and develops allogeneic CAR-NK cell therapies for the treatment of cancer. Read more
Catamaran Bio is a biotechnology company that researches and develops allogeneic CAR-NK cell therapies for the treatment of cancer. Read more
Catamaran Bio is a biotechnology company that researches and develops allogeneic CAR-NK cell therapies for the treatment of cancer. Read more
President & CEO
Alvin Shih
Nkarta is perceived as one of Catamaran Bio's biggest rivals. Nkarta is headquartered in South San Francisco, California, and was founded in 2015. Like Catamaran Bio, Nkarta also operates in the Biotechnology industry. Nkarta generates 2.31% the revenue of Catamaran Bio.
No recent acquisitions found related to Catamaran Bio
Since Catamaran Bio was founded in 2020, it has participated in 1 round of funding. In total Catamaran Bio has raised $42.0M. Catamaran Bio's funding round was on Nov 2020 for a total of $42.0M
No recent investments found related to Catamaran Bio
610 Main Street
Cambridge, Massachusetts02139
Driving Directions »